Palatin Technologies, Inc. Common Stock Asset Resilience Ratio
Palatin Technologies, Inc. Common Stock asset resilience ratio. Palatin Technologies, Inc. Common Stock (PTN) has an Asset Resilience Ratio of 80.75% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See PTN cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Palatin Technologies, Inc. Common Stock (1999–2025)
Asset resilience ratio of Palatin Technologies, Inc. Common Stock from 1999 to 2025. This chart shows how Palatin Technologies, Inc. Common Stock's Asset Resilience Ratio has changed over time. Read Palatin Technologies, Inc. Common Stock (PTN) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Palatin Technologies, Inc. Common Stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see balance sheet size of Palatin Technologies, Inc. Common Stock.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $14.48 Million | 80.75% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $14.48 Million | 80.75% |
Asset Resilience Insights
- Very High Liquidity: Palatin Technologies, Inc. Common Stock maintains exceptional liquid asset reserves at 80.75% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Palatin Technologies, Inc. Common Stock Industry Peers by Asset Resilience Ratio
Compare Palatin Technologies, Inc. Common Stock's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Palatin Technologies, Inc. Common Stock Asset Resilience Ratio by Year (1999–2025)
Palatin Technologies, Inc. Common Stock asset resilience ratio by year from 1999 to 2025. The table below shows the annual Asset Resilience Ratio data for Palatin Technologies, Inc. Common Stock.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-06-30 | 78.49% | $2.56 Million | $3.27 Million | -10.20pp |
| 2024-06-30 | 88.69% | $9.53 Million | $10.74 Million | +27.47pp |
| 2023-06-30 | 61.22% | $10.98 Million | $17.94 Million | -21.78pp |
| 2022-06-30 | 83.00% | $29.94 Million | $36.07 Million | -6.31pp |
| 2021-06-30 | 89.31% | $60.10 Million | $67.30 Million | -8.10pp |
| 2020-06-30 | 97.41% | $82.85 Million | $85.05 Million | +55.87pp |
| 2019-06-30 | 41.54% | $43.51 Million | $104.74 Million | -56.49pp |
| 2018-06-30 | 98.03% | $38.25 Million | $39.02 Million | +26.86pp |
| 2017-06-30 | 71.17% | $40.45 Million | $56.83 Million | +58.68pp |
| 2016-06-30 | 12.49% | $1.38 Million | $11.05 Million | -- |
| 2015-06-30 | 0.00% | $0.00 | $29.47 Million | -- |
| 2014-06-30 | 0.00% | $0.00 | $12.56 Million | -- |
| 2013-06-30 | 20.94% | $5.25 Million | $25.07 Million | +14.43pp |
| 2012-06-30 | 6.50% | $350.00K | $5.38 Million | -21.44pp |
| 2010-06-30 | 27.95% | $3.46 Million | $12.39 Million | +1.89pp |
| 2009-06-30 | 26.06% | $3.44 Million | $13.20 Million | +8.53pp |
| 2008-06-30 | 17.53% | $3.35 Million | $19.12 Million | +12.10pp |
| 2007-06-30 | 5.43% | $2.32 Million | $42.78 Million | -0.39pp |
| 2006-06-30 | 5.82% | $2.33 Million | $40.05 Million | -0.96pp |
| 2005-06-30 | 6.78% | $2.39 Million | $35.17 Million | -3.33pp |
| 2004-06-30 | 10.11% | $2.47 Million | $24.38 Million | -7.88pp |
| 2003-06-30 | 17.99% | $4.09 Million | $22.72 Million | -6.27pp |
| 2000-06-30 | 24.26% | $2.16 Million | $8.89 Million | +13.62pp |
| 1999-06-30 | 10.64% | $500.00K | $4.70 Million | -- |
About Palatin Technologies, Inc. Common Stock
Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, … Read more